Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets: 2012-2025

Historic Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $352.6 million.

  • Agios Pharmaceuticals' Non-Current Assets fell 50.86% to $352.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.6 million, marking a year-over-year decrease of 50.86%. This contributed to the annual value of $697.6 million for FY2024, which is 575.42% up from last year.
  • Agios Pharmaceuticals' Non-Current Assets amounted to $352.6 million in Q3 2025, which was down 21.95% from $451.8 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Assets peaked at $717.6 million during Q3 2024, and registered a low of $103.3 million during Q4 2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Non-Current Assets value was $352.6 million (recorded in 2025), while the average stood at $384.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 74.56% in 2023, then skyrocketed by 575.42% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Assets (Quarterly) stood at $373.5 million in 2021, then increased by 8.69% to $405.9 million in 2022, then tumbled by 74.56% to $103.3 million in 2023, then spiked by 575.42% to $697.6 million in 2024, then crashed by 50.86% to $352.6 million in 2025.
  • Its last three reported values are $352.6 million in Q3 2025, $451.8 million for Q2 2025, and $586.9 million during Q1 2025.